User menu

Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.

Bibliographic reference Haczeyni, Fahrettin ; Poekes, Laurence ; Wang, Hans ; Mridha, Auvro R ; Barn, Vanessa ; et. al. Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.. In: Obesity : a research journal, Vol. 25, no.1, p. 155-165 (2017)
Permanent URL http://hdl.handle.net/2078.1/180098
  1. Loomba Rohit, Abraham Maria, Unalp Aynur, Wilson Laura, Lavine Joel, Doo Ed, Bass Nathan M., , Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis, 10.1002/hep.25772
  2. Neuschwander-Tetri Brent A., Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites, 10.1002/hep.23719
  3. Nakamura Manabu T., Yudell Barbara E., Loor Juan J., Regulation of energy metabolism by long-chain fatty acids, 10.1016/j.plipres.2013.12.001
  4. Klöting Nora, Blüher Matthias, Adipocyte dysfunction, inflammation and metabolic syndrome, 10.1007/s11154-014-9301-0
  5. De Minicis Samuele, Day Chris, Svegliati-Baroni Gianluca, From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights, 10.2174/1381612811319290006
  6. Farrell Geoffrey C., Wong Vincent Wai-Sun, Chitturi Shiv, NAFLD in Asia—as common and important as in the West, 10.1038/nrgastro.2013.34
  7. Larter Claire Z, Chitturi Shiv, Heydet Déborah, Farrell Geoffrey C, A fresh look at NASH pathogenesis. Part 1: The metabolic movers, 10.1111/j.1440-1746.2010.06253.x
  8. Cusi Kenneth, Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications, 10.1053/j.gastro.2012.02.003
  9. Haczeyni Fahrettin, Barn Vanessa, Mridha Auvro R., Yeh Matthew M., Estevez Emma, Febbraio Mark A., Nolan Christopher J., Bell-Anderson Kim S., Teoh Narci C., Farrell Geoffrey C., Exercise improves adipose function and inflammation and ameliorates fatty liver disease in obese diabetic mice : Exercise Improves Adipose Dysfunction in Obesity, 10.1002/oby.21170
  10. Chitturi S, NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome, 10.1053/jhep.2002.30692
  11. Manchanayake Jayani, Chitturi Shivakumar, Nolan Christopher, Farrell Geoffrey C, Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease : Hyperinsulinemia in fatty liver, 10.1111/j.1440-1746.2010.06528.x
  12. Larter Claire Z, Yeh Matthew M, Van Rooyen Derrick M, Teoh Narci C, Brooling John, Hou Jing Yun, Williams Jacqueline, Clyne Matthew, Nolan Christopher J, Farrell Geoffrey C, Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice, 10.1111/j.1440-1746.2009.05996.x
  13. Gastaldelli Amalia, Harrison Stephen A., Belfort-Aguilar Renata, Hardies Lou Jean, Balas Bogdan, Schenker Steven, Cusi Kenneth, Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis, 10.1002/hep.23116
  14. Oh Sechang, Shida Takashi, Yamagishi Kazumasa, Tanaka Kiyoji, So Rina, Tsujimoto Takehiko, Shoda Junichi, Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: A retrospective study, 10.1002/hep.27544
  15. Singh Siddharth, Khera Rohan, Allen Alina M., Murad M. Hassan, Loomba Rohit, Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis : HEPATOLOGY, Vol. XX, No. X, 2015, 10.1002/hep.27999
  16. Vilar-Gomez Eduardo, Martinez-Perez Yadina, Calzadilla-Bertot Luis, Torres-Gonzalez Ana, Gra-Oramas Bienvenido, Gonzalez-Fabian Licet, Friedman Scott L., Diago Moises, Romero-Gomez Manuel, Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis, 10.1053/j.gastro.2015.04.005
  17. Pellicciari Roberto, Fiorucci Stefano, Camaioni Emidio, Clerici Carlo, Costantino Gabriele, Maloney Patrick R., Morelli Antonio, Parks Derek J., Willson Timothy M., 6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity, 10.1021/jm025529g
  18. Mencarelli A., Renga B., Migliorati M., Cipriani S., Distrutti E., Santucci L., Fiorucci S., The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis, 10.4049/jimmunol.0901347
  19. Fiorucci S., Cipriani S., Mencarelli A., Baldelli F., Bifulco G., Zampella A., Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA, 10.2174/138955711796355258
  20. Rizzo G., Disante M., Mencarelli A., Renga B., Gioiello A., Pellicciari R., Fiorucci S., The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo, 10.1124/mol.106.023820
  21. Maneschi E., Vignozzi L., Morelli A., Mello T., Filippi S., Cellai I., Comeglio P., Sarchielli E., Calcagno A., Mazzanti B., Vettor R., Vannelli G. B., Adorini L., Maggi M., FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS, 10.1530/joe-13-0109
  22. Cipriani Sabrina, Mencarelli Andrea, Palladino Giuseppe, Fiorucci Stefano, FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats, 10.1194/jlr.m001602
  23. Teodoro João Soeiro, Rolo Anabela Pinto, Palmeira Carlos Marques, Hepatic FXR: key regulator of whole-body energy metabolism, 10.1016/j.tem.2011.07.002
  24. Abdelkarim Mouaadh, Caron Sandrine, Duhem Christian, Prawitt Janne, Dumont Julie, Lucas Anthony, Bouchaert Emmanuel, Briand Olivier, Brozek John, Kuipers Folkert, Fievet Catherine, Cariou Bertrand, Staels Bart, The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-γ and Interfering with the Wnt/β-Catenin Pathways, 10.1074/jbc.m110.166231
  25. Neuschwander-Tetri Brent A, Loomba Rohit, Sanyal Arun J, Lavine Joel E, Van Natta Mark L, Abdelmalek Manal F, Chalasani Naga, Dasarathy Srinivasan, Diehl Anna Mae, Hameed Bilal, Kowdley Kris V, McCullough Arthur, Terrault Norah, Clark Jeanne M, Tonascia James, Brunt Elizabeth M, Kleiner David E, Doo Edward, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, 10.1016/s0140-6736(14)61933-4
  26. Heydet Déborah, Chen Lesley X., Larter Claire Z., Inglis Chrystal, Silverman Michael A., Farrell Geoffrey C., Leroux Michel R., A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice, 10.1002/dneu.22031
  27. Arsov Todor, Silva Diego G., O’Bryan Moira K., Sainsbury Amanda, Lee Nicola J., Kennedy Claire, Manji Shehnaaz S.M., Nelms Keats, Liu Conan, Vinuesa Carola G., de Kretser David M., Goodnow Christopher C., Petrovsky Nikolai, Fat Aussie—A New Alström Syndrome Mouse Showing a Critical Role for ALMS1 in Obesity, Diabetes, and Spermatogenesis, 10.1210/me.2005-0494
  28. Farrell Geoffrey C., Mridha Auvro R., Yeh Matthew M., Arsov Todor, Van Rooyen Derrick M., Brooling John, Nguyen Tori, Heydet Deborah, Delghingaro-Augusto Viviane, Nolan Christopher J., Shackel Nicholas A., McLennan Susan V., Teoh Narci C., Larter Claire Z., Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype, 10.1111/liv.12335
  29. Ram�rez-Zacar�as J. L., Castro-Mu�ozledo F., Kuri-Harcuch W., Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with oil red O, 10.1007/bf00316069
  30. Silversand Christer, Haux Carl, Improved high-performance liquid chromatographic method for the separation and quantification of lipid classes: application to fish lipids, 10.1016/s0378-4347(97)00385-x
  31. Kleiner David E., Brunt Elizabeth M., Van Natta Mark, Behling Cynthia, Contos Melissa J., Cummings Oscar W., Ferrell Linda D., Liu Yao-Chang, Torbenson Michael S., Unalp-Arida Aynur, Yeh Matthew, McCullough Arthur J., Sanyal Arun J., , Design and validation of a histological scoring system for nonalcoholic fatty liver disease, 10.1002/hep.20701
  32. Chau You-Ying, Bandiera Roberto, Serrels Alan, Martínez-Estrada Ofelia M., Qing Wei, Lee Martin, Slight Joan, Thornburn Anna, Berry Rachel, McHaffie Sophie, Stimson Roland H., Walker Brian R., Chapuli Ramon Muñoz, Schedl Andreas, Hastie Nick, Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source, 10.1038/ncb2922
  33. Van Rooyen Derrick M., Gan Lay T., Yeh Matthew M., Haigh W. Geoffrey, Larter Claire Z., Ioannou George, Teoh Narci C., Farrell Geoffrey C., Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome, 10.1016/j.jhep.2013.02.024
  34. Horie Takahiro, Nishino Tomohiro, Baba Osamu, Kuwabara Yasuhide, Nakao Tetsushi, Nishiga Masataka, Usami Shunsuke, Izuhara Masayasu, Nakazeki Fumiko, Ide Yuya, Koyama Satoshi, Sowa Naoya, Yahagi Naoya, Shimano Hitoshi, Nakamura Tomoyuki, Hasegawa Koji, Kume Noriaki, Yokode Masayuki, Kita Toru, Kimura Takeshi, Ono Koh, MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo, 10.1038/srep05312
  35. Poekes L., Lanthier N., Leclercq I. A., Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome, 10.1042/cs20150339
  36. Ma Yongjie, Huang Yixian, Yan Linna, Gao Mingming, Liu Dexi, Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance, 10.1007/s11095-013-0986-7
  37. Jiang Changtao, Xie Cen, Lv Ying, Li Jing, Krausz Kristopher W., Shi Jingmin, Brocker Chad N., Desai Dhimant, Amin Shantu G., Bisson William H., Liu Yulan, Gavrilova Oksana, Patterson Andrew D., Gonzalez Frank J., Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction, 10.1038/ncomms10166
  38. Fang Sungsoon, Suh Jae Myoung, Reilly Shannon M, Yu Elizabeth, Osborn Olivia, Lackey Denise, Yoshihara Eiji, Perino Alessia, Jacinto Sandra, Lukasheva Yelizaveta, Atkins Annette R, Khvat Alexander, Schnabl Bernd, Yu Ruth T, Brenner David A, Coulter Sally, Liddle Christopher, Schoonjans Kristina, Olefsky Jerrold M, Saltiel Alan R, Downes Michael, Evans Ronald M, Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance, 10.1038/nm.3760
  39. Fiorucci Stefano, Distrutti Eleonora, Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders, 10.1016/j.molmed.2015.09.001
  40. Larter Claire Z., Yeh Matthew M., Williams Jacqueline, Bell-Anderson Kim S., Farrell Geoffrey C., MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes, 10.1016/j.jhep.2008.03.026